Iodine supplementation during pregnancy is a common practice in developed countries. However, scant evidence is available regarding the safety and effectiveness of maternal iodine supplementation with regard to child neuropsychological development. We previously reported an inverse association between iodine supplementation and the psychomotor development of infants in a birth cohort from Valencia, Spain. In the present study, we assessed this association in a wider sample of mother and child pairs from 3 other regions in Spain. Neuropsychological development was assessed using the Bayley Scales of Infant Development in 1,519 infants (median age, 16 months) between 2006 and 2009. In multivariate analyses, maternal consumption of 150 μg/day or more of iodine from supplements was related to a 1.5-fold increase in the odds of a psychomotor score less than 85 (95% confidence interval: 0.8, 2.9) and to a 1.7-fold increase in the odds of a mental score less than 85 (95% confidence interval: 0.9, 3.0). Findings previously reported in the Valencia cohort were only partially verified. The results of the present study suggest that, at least in these regions, iodine supplementation does not improve infant neuropsychological development at 1 year of age. Further research is needed on the risks and benefits of supplementary iodine for both maternal thyroid function and child neurodevelopment. child development; dietary supplements; fetal development; iodine; prenatal nutritional physiological phenomena Abbreviations: CI, confidence interval; INMA, Infancia y Medio Ambiente-Childhood and Environment; MS, mental scale; PS, psychomotor scale; UIC, urinary iodine concentration.
Systematic iodine supplementation during pregnancy is a current common practice in developed countries, even in those countries in which the population's iodine nutritional status has been considered adequate (e.g., the United States) (1) . This practice has been justified by arguing that the potential small risks of excess iodine intake are outweighed by the substantial hazards of iodine deficiency during pregnancy. Severe iodine deficiency causes maternal thyroid disorders, which can affect normal fetal brain maturation and developmental achievement in children (2) . It is still uncertain whether mild-to-moderate maternal iodine deficiency affects cognitive function in the offspring (3) .
On the other hand, supplementary or excessive iodine intake has been related to altered thyroid hormone levels during pregnancy in both mothers (4-7) and neonates (8) and to a higher prevalence of subclinical and even overt hypothyroidism in the general population and in women of reproductive age (9) (10) (11) (12) . However, scant evidence is available on the safety and long-term effectiveness of iodine supplementation during pregnancy in relation to child development, and the few studies published to date showed controversial results. A clinical trial carried out in an area of Spain in which the population was mildly iodine-deficient (5) found that offspring of pregnant women who had taken iodine supplements had better neuropsychological scores in early infancy. Project Viva, carried out in an iodine-sufficient area of United States, did not find any relationship between iodine-containing vitamin consumption during pregnancy and cognitive development of the offspring (13) . As part of the Spanish Infancia y Medio Ambiente-Environment and Childhood (INMA) Study (14) , we found in a sample of women from the Valencia region, an iodine-sufficient area, that maternal consumption of multivitamins containing iodine was related to lower psychomotor achievement of their infants at 1 year of age (15) .
Therefore, further evidence is needed about the effectiveness and safety of maternal iodine supplementation and its relation to child development, especially in iodine-sufficient populations. As far as we know, our study (15) was the first reported to date in which a potential risk for infant neuropsychological development was associated with maternal iodine supplementation. To assess whether this finding could be confirmed in other populations, we assessed the association of maternal iodine supplementation with the cognitive and psychomotor development of infants at 1 year of age in a wider sample of mother and child pairs from 3 other regions in Spain (Asturias, Gipuzkoa, and Sabadell) that had different iodine supplementation practices and coverage.
MATERIALS AND METHODS

Population and study design
The study population is part of the INMA project. This multicenter mother and child cohort study was established in Spain between 2003 and 2008 in the regions of Valencia, Sabadell (Catalonia), Asturias, and Gipuzkoa (Basque Country) using a common protocol (14) . The present analysis is based on data from the cohorts in Sabadell, Asturias, and Gipuzkoa.
Women were enrolled during their first antenatal care visit to the main public hospital or health center of reference and were followed through pregnancy. There were 1,789 women who agreed to participate and met the inclusion criteria (≥16 years of age, singleton pregnancy, intention to deliver at the reference hospital, no communication handicap, and no assisted conception). After excluding the women who withdrew from the study, were lost to follow-up, had induced or spontaneous abortions, or had fetal deaths, we had a total sample of 1,719 women who delivered a live infant between October 2004 and August 2008. Of them, 1,532 (89%) were evaluated for neuropsychological development at 1 year of age (February 2006-October 2009). All participants provided informed consent, and the research protocol was approved by the ethics committees of the centers involved in the study.
Neuropsychological assessment
Cognitive and psychomotor development of infants was evaluated using the Bayley Scales of Infant Development (16) . The tests were administered by trained psychologists when the children were at a mean age of 16.0 months (range, 12-30 months). Thirteen children who were older than 23 months of age at testing were excluded from the analysis, leaving a final sample of 1,519 children. The mental scale (MS) consisted of 163 items that assessed cognitive development in areas such as performance ability, memory, and first verbal learning. The psychomotor scale (PS) consisted of 81 items that assessed fine and gross psychomotor development. Special conditions at the time of testing that could affect the quality of the Bayley evaluation were registered (e.g., rejecting behaviors, irritability, tiredness, sleepiness, being feverish). Raw scores were standardized for the psychologist who administered the test and the child's age at evaluation using parametric methods for the estimation of age-specific reference intervals (17) . Standardized residuals were typified to a mean of 100 with a standard deviation of 15 points to homogenize the scales. Dichotomous variables were defined, with a score 1 standard deviation below the mean indicating a slight delay in neuropsychological development (score <85).
Assessment of iodine intake
Usual dietary iodine intake was calculated by averaging estimates from a 100-item semiquantitative food frequency questionnaire that was administered twice to pregnant women at 10-13 weeks and 28-32 weeks of gestation and that covered intakes from the last menstrual period until the third trimester of pregnancy. The food frequency questionnaire was an adapted version of the Willett questionnaire (18) that had been validated and developed for an adult Spanish population in Valencia (19) . The iodine contents of the food items were primarily obtained from food composition tables from the US Department of Agriculture (20) and adjusted for total energy intake using the residual method (21) . Information on the consumption of iodized salt and the use of specific potassium iodide supplements or vitamin/ mineral preparations containing iodine was collected using a structured questionnaire. Iodine intake from supplements was estimated based on the supplement brand name and composition, daily dose, and timing of consumption. Mean supplementary iodine intake during the months of consumption was classified as a mean dose <100 μg/day, 100-149 μg/day, or ≥150 μg/day (range, 150-400 μg/day).
Urinary iodine concentration (UIC) was measured in spot samples collected at the end of the first trimester of pregnancy using paired-ion reversed-phase high-performance liquid chromatography with electrochemical detection and a silver working electrode (22) . Urine samples were stored at −20°C until they were delivered to the reference laboratory (Normative Public Health Laboratory of Bilbao, Basque Country). UIC was categorized according to the World Health Organization recommended range for pregnant women (150-249 μg/L) (23) . The association between iodine intake and UIC has already been described in this population (24) .
Other covariates
Questionnaires administered by personal interview in the first and third trimesters were used to collect maternal characteristics: age, country of origin, educational level, social class, prepregnancy body mass index, smoking, and parity. Previous history of thyroid disease, child sex, birth weight, and length of gestation were obtained from maternal and infant clinical records. At the time of the neuropsychological testing, information on maternal smoking, cohabitation, working status, breastfeeding duration, and the child's main care provider and day-care center attendance was also collected.
Statistical analysis
Multiple linear regression was used to estimate associations between the Bayley Scales of Infant Development scores and maternal iodine intake variables. Logistic regression models were defined in which a score 1 standard deviation below the mean identified a slight delay in neuropsychological development. Different models were developed to study the association among the MS and PS scores and 1) maternal iodine intake variables from different sources: iodized salt, diet, and supplements and 2) maternal urinary iodine concentration. Covariates were selected as follows: Models were adjusted for cohort, child's sex, maternal age, and maternal history of thyroid disease. Initial models also included the covariates related to the outcome at P < 0.20. Following a backward elimination procedure, potential predictors were excluded from the analysis if they were not related with the outcome at P < 0.10. Irrespective of their statistical significance, the previous variables were retained in the models if their exclusion changed the magnitude of the main effects by more than 10%.
To account for clustering and possible heterogeneity, the final models were stratified by cohort, including all previously specified covariates except cohort, and subsequent meta-analysis was used to obtain combined estimates. Heterogeneity was quantified by means of the I 2 statistic (25). With levels above 50%, the random-effects model was applied to obtain combined estimates.
In sensitivity analysis, the robustness of the results was evaluated after the exclusion of women with a history of thyroid disease (96 cases), preterm deliveries (58 cases), children in treatment for pathologies that could affect infant neurodevelopment (including hypotonia, plagiocephalia, or shortening of the sternocleidomastoid muscle; 10 cases), or children with potential low quality of the test results because of special conditions at the time of the Bayley evaluation (e.g., rejecting behaviors, irritability, tiredness, sleepiness, being feverish; 100 cases). Additional sensitivity models included the covariates fetal growth restriction and gestational age at delivery because in theory, they are also potential mediators of the associations of interest. We also verified whether associations varied significantly according to child's sex-based on the interaction observed in the Valencia cohort (15)-or if the accumulation of iodine intake from different sources (iodized salt plus supplements) could have a nonadditive effect.
Statistical analyses were conducted with R, version 2.14.2 (R Foundation for Statistical Computing, Vienna, Austria) and Stata, version 11.0 (StataCorp LP, College Station, Texas).
RESULTS
The distribution of iodine-related variables and development scores, stratified by cohort, are displayed in Table 1 .
Iodine-related variables differed among areas (P < 0.001). Women from Sabadell showed the lowest prevalence of iodized salt consumption (17.9%). The highest median iodine intake from diet was achieved in Asturias (189 µg/day), with levels of approximately 150 µg/day in the rest of the cohorts. Almost all women in Gipuzkoa consumed at least 100 µg/day of iodine from supplements during pregnancy (97.6%), as did more than half in Asturias (60.5%) but only a few women in Sabadell (9.2%). In Gipuzkoa, almost all of the women consumed a specific potassium iodide supplement, whereas in Sabadell and Asturias, women also took multivitamin preparations containing iodine. UIC varied among cohorts in the same way as iodine intake from supplements and salt, with the highest median level found in Gipuzkoa (169 µg/L) and the lowest in Sabadell (90 µg/L). Children were evaluated for neuropsychological development at earlier ages in Sabadell and Gipuzkoa (median age, 14.5 months) than in Asturias (median, 19.1 months).
In Table 2 , we compared MS and PS scores according to iodine intake variables, stratified by cohort. No significant differences were observed except for PS scores and intake of supplements containing iodine in Asturias. Infants of mothers who took a mean dose of 150 µg/day or more during pregnancy showed the lowest mean PS score (93.3) compared with the infants of mothers taking 100-149 µg/day (PS score of 100.5) or less than 100 µg/day (PS score of 98.2). The associations of maternal characteristics according to the different measures of iodine status are presented in Web Table 1 (available at http://aje.oxfordjournals.org/).
In combined adjusted analyses, we observed that infants from mothers with UICs in the range of 150-249 μg/L had a 2.3-point increase in MS score (95% confidence interval (CI): −0.2, 4.9) compared with those whose mothers had a UIC less than 100 μg/L, although this association did not reach statistical significance (Table 3) . Iodine intakes from neither diet nor salt were associated with MS or PS scores. An intake of 150 µg/day or more of iodine supplements, when compared with none or less than 100 µg/day, was related to an increased risk of a MS score less than 85 (OR = 1.7, 95% CI: 0.9, 3.0) and a PS score less than 85 (OR = 1.5, 95% CI: 0.8, 2.9), although these associations were nonsignificant at P < 0.05. An intake of 150 μg/day or more of iodine supplements was also related to a decrease of 1.8 points (95% CI: −5.6, 2.0) in MS scores and 0.9 points (95% CI: −6.9, 5.0) in PS scores. All of these results were homogeneous among cohorts (I 2 < 50%) except for the association between continuous PS scores and supplement intake (variation in estimate attributable to heterogeneity: I 2 = 56%, P(Cochran Q) = 0.10), with a negative association in Asturias but not in Gipuzkoa and Sabadell. Therefore, this combined estimate was obtained from random-effects meta-analysis.
We did not find significant or consistent variations in these associations according to the starting time of supplement intake (before or after the end of the first trimester of pregnancy) or the type of supplement (combined or specific) once we accounted for the dose (data not shown).
In the already reported study in the Valencia cohort (15), maternal intake of 150 µg/day or more of iodine from supplements was associated with a significant decrease in the PS score and with an increase in the odds of a PS score less than 85 (OR = 1.8, 95% CI: 1.0, 3.3), whereas no relationship was observed with the MS score. To assess the consistency of the results among the different populations, we compared the association between iodine intake from supplements (<100 μg/day vs. ≥150 μg/day) and infant neuropsychological development in the different geographic regions (Figure 1 ), including the estimates already reported in the Valencia cohort (15) . Figure 1 also shows the overall estimates for the 3 sites (shown in Table 3 ) excluding Valencia, as well as for all 4 sites together. The main variation was observed in relation to the PS scores, as the Valencia cohort had an inverse relationship similar to that observed in Asturias. Therefore, the overall estimates for PS scores were strengthened, reaching the statistical significance for a PS score less than 85 (OR = 1.7, 95% CI: 1.1, 2.6). Sensitivity analyses (Figure 2 ) did not substantially affect the estimates, except for a reduction in the risk of a MS score less than 85 after the exclusion of women with a history of thyroid disease (OR = 1.2; 95% CI: 0.6, 2.5) or children with a low-quality Bayley test (OR = 1.3; 95% CI: 0.7, 2.6). No significant interaction term was found between iodine supplements and iodized salt use or sex. When models were stratified according to iodized salt use, the associations were strengthened in the group of users. This difference was more evident in the PS scores when the analysis was based on the population from the 4 cohorts: The odds ratio was 2.1 (95% CI: 1.2, 3.8) in users versus 1.2 (95% CI: 0.6, 2.4) in nonusers.
DISCUSSION
We previously reported that in mother and child pairs from the Valencia INMA cohort, maternal consumption of 150 μg/day or more of iodine from multivitamins was related to lower psychomotor achievement of their infants at 1 year of age (15) . In the present analysis, we reassessed this association in a wider sample from 3 other regions in Spain (Asturias, Gipuzkoa, and Sabadell) using a common protocol.
Maternal UIC, iodized salt consumption, and dietary iodine intake during pregnancy were not associated with neuropsychological development. Consumption during pregnancy of 150 μg/day or more of iodine from multivitamins or specific supplements was related to a decrease in PS scores, although only significantly so in Asturias. This level of consumption, compared with less than 100 μg/day, was related in the overall sample to a 1.5-fold increase in the odds of a PS score less than 85 and to a 1.7-fold increase in the odds of a MS score less than 85, although these results did not reach statistical significance. When the reported estimates from the Valencia cohort (15) were included in the meta-analyses, the overall estimates for PS scores were reinforced (OR = 1.7, 95% CI: 1.1, 2.6). When analyses were stratified by maternal iodized salt consumption, this association Abbreviations: CI, confidence interval; OR, odds ratio. a Cohort-specific models were combined using meta-analysis. All models were adjusted for maternal age, sex, and history of thyroid disease. Models for mental scale were also adjusted for maternal origin, mixed social class, breastfeeding, and main child minder (continuous) and for mixed social class (dichotomous). Models for psychomotor scale were also adjusted for maternal parity and main child minder (continuous) and for maternal origin, mixed social class, educational level, parity, and employment at 1 year of age (dichotomous).
b Results from random effects meta-analysis (I 2 > 50%).
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was strengthened for women who consumed iodized salt, suggesting that the extra dose of iodine from supplements might result in iodine excess, which can induce thyroid dysfunction. Some evidence is already available regarding the link between supplementary or excessive iodine intake and maternal (5-7) and fetal (8) thyroid dysfunction. It is unclear whether the major mechanism is iodine triggering thyroid autoimmunity or a direct inhibitory effect on thyroid hormone production (26) . Moreover, the risk of iodine-induced hypothyroidism appears to be greater in formerly iodinedeficient populations (27) .
We previously reported an increased risk of raised thyroidstimulating hormone during the first half of pregnancy for women who consumed supplements containing iodine; in addition, we found an association between supplement consumption and lower levels of free thyroxin, but only in women from Sabadell (6) . The cohort of Asturias was not included in that report because its data were not available at that time. We have now reanalyzed the association between supplement intake and thyroid hormone levels in the first half of pregnancy including the 4 study areas, and the results support the association already reported for both thyroid-stimulating hormone and free thyroxin (Web Figure 1) .
The link between gestational iodine supplementation and altered thyroid hormone levels has been recently corroborated in a cohort of anti-thyroid antibody-negative pregnant women from a mild-to-moderately iodine-deficient area in Italy (7) . Daily supplementation with 150 μg/day of iodine from early pregnancy was associated with a significantly lower concentration of both triiodothyronine and free thyroxin and with higher concentrations of thyroid-stimulating hormone throughout the pregnancy than was regular use of iodized salt before becoming pregnant. Although the authors recognized that prolonged use of iodized salt is associated with better maternal thyroid function, they surprisingly recommended that all women of child-bearing age should take iodine supplements. This type of recommendation should be taken with caution if we take into account that thyroid dysfunction during pregnancy has been related to child neuropsychological development in several studies from areas with different iodine statuses (28) (29) (30) (31) (32) and even in our own study population (15, 33) . There is scant evidence regarding the effects of maternal iodine supplementation on child neuropsychological development in mildly iodine-deficient (5, 34) and iodine-sufficient populations (13) . Two recently reported nonrandomized trials carried out in mildly iodine-deficient areas in Spain (5, 34) found higher developmental scores in children whose mothers were supplemented from early pregnancy, although the results should be taken with caution because of some methodological limitations that have already been discussed in detail elsewhere (15, 35) .
Our results suggest that, at least in these regions, iodine supplementation does not improve infant neuropsychological development at 1 year of age. The results of this analysis based on the 3 sites are partly consistent with those already reported in the Valencia cohort (15) . Although in Valencia, no association was observed with the MS scores, an inverse association with the PS scores was reported, similar to what was found in Asturias (Figure 1) . One possible explanation for the lack of associations in Gipuzkoa and Sabadell might be the reduced power to detect differences within each area, given the homogeneous pattern of consumption (almost all women consumed at least 100 μg/day of iodine supplements in Gipuzkoa and less than 10% did so in Sabadell).
Moreover, Valencia presented a higher proportion of women who consumed iodine supplements at a dose of 300 μg/day or more (24) than did the other cohorts. The analysis based on the 3 sites did not ratify, however, the interaction with sex found in Valencia.
Our study presents several limitations. Although we adjusted for a wide range of potential risk factors, other potential confounding or modifier effects for which we did not account cannot be dismissed. It can be argued that mothers who are at a higher risk of poor reproductive outcomes because of medical or social conditions are more likely to be recommended to take supplements. The main source of iodine supplementation was a specific potassium iodide preparation given as part of iodine supplementation programs routinely implemented during pregnancy, which in Asturias and Sabadell were started at the middle or at the end of the recruitment period. Apart from that, no association was observed between iodine supplementation and maternal characteristics except for maternal age, country of origin, and social class (Web Table 1 ), but we accounted for these variables in the multivariate models. Iodine supplementation was not associated with preterm birth, low birth weight, Apgar score, or type of delivery (data not shown).
Maternal thyroid autoimmunity has also been shown to be related to poor neuropsychological achievement in several studies (31, 36) . Unfortunately, thyroid antibodies were not measured in our study population, precluding the assessment of its role in the observed association between supplement intake and child development. Intelligence quotients of parents and measurements of the quality of the home environment were also not available.
On the other hand, the multicenter structure of this study and the wide range of iodine status and supplementation patterns can be considered strengths of the study because results can be extrapolated to a more extensive range of situations. The consistency of the results related to dichotomous outcomes by cohort and in most of the sensitivity analyses that we applied reinforced these results. Moreover, the cohort design of the INMA Study allowed us to control for a wide variety of confounding variables and the blinded and homogeneous conditions in which the children of the supplemented and nonsupplemented women were evaluated. We are aware of the limited validity of Bayley Scales of Infant Development scores at this early age for predicting later cognitive performance, but the INMA Study provides the opportunity of verifying long-term effects in future evaluations.
In summary, the results of the present study do not support a beneficial impact of maternal iodine supplementation on neuropsychological development of infants from iodinesufficient or mildly iodine-deficient areas. Contrarily, an association of iodine supplements with a poorer mental and psychomotor achievement was shown, with the latter being significant in Asturias and Valencia. This association was more pronounced in children whose mothers consumed iodized salt, suggesting an excess of iodine intake. These results contrast with the extended recommendation of systematic iodine supplementation during pregnancy even in iodine-sufficient populations, a preventive practice that is being applied without sufficient evidence on its safety and long-term effectiveness. Further research is needed, as well as surveillance and public debate on this practice and its health consequences.
